MassGeneral Institute for Neurodegenerative Disease

Translating today's discoveries into tomorrow's cures

Facebook icon Twitter Icon

Lagier-Tourenne, Clotilde, MD, PhD

Biography
Affiliations

Clotilde Lagier-Tourenne performs patient-oriented research to understand the molecular mechanisms driving neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and to develop therapeutic strategies. Mutations and/or cellular mislocalization of several RNA binding proteins have been identified as central components in the pathogenesis of ALS and FTD. Using innovative cellular and genomics techniques, Lagier-Tourenne’s group explores the regulatory networks between RNA binding proteins and changes in RNA expression that occur in these diseases.

Moir, Robert, PhD

Biography
Affiliations

Robert Moir’s research focuses on the biochemical and cellular mechanisms of neurodegeneration in Alzheimer's disease (AD) and aging. His work has uncovered new therapeutic targets aimed at preventing the accumulation of beta-amyloid (Aβ), the primary neurotoxic agent in AD. Moir was the first to identify the low-density lipoprotein receptor protein (LRP) as the mediator of an important early step in Aβ production in the brain. Today, LRP-mediated Aβ clearance pathways are increasingly recognized as major targets for therapeutic intervention.

Zhang, Can (Martin), MD, PhD

Biography
Affiliations

Can (Martin) Zhang’s research is focused on identifying the mechanism of neurodegeneration in Alzheimer’s disease (AD), with the goal of identifying molecular targets and biomarkers that will translate into the development of novel therapeutic strategies for AD. The pathogenesis of AD is believed to be primarily driven by amyloid-B (AB), the principal component of senile plaques in the brain.

Pages